Elixir Medical Corp

Innovation for Life. Elixir Medical is committed to transforming care for patients with heart and vascular disease through innovation.

[Elixir Medical Corp @ElixirMed]

A critical moment for PCI!

Researchers presented the latest data – 4 years after the procedure – from the BIOADAPTOR RCT at #EuroPCR2026, comparing DynamX bioadaptor to a contemporary drug-eluting stent.

The big news:
66% reduction in target lesion failure (TLF) for DynamX bioadaptor compared to DES.

We’re excited to see the impact of the bioadaptor’s innovative unlocking technology on patient outcomes. The incidence curve of major adverse cardiac events in the years after PCI really is flattening.

#EuroPCR #DynamX #Bioadaptor #RCT #ClinicalData #Cardiology

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States)
law to investigational use.

PMN 2475 Rev A

[Elixir Medical Corp @ElixirMed]

It was a full house for our bioadaptor symposium!

Our expert faculty led by Stefan Verheye, Davide Capodanno, and Nikos Werner provided a deep dive into the latest clinical evidence and the unique mechanism of action for bioadaptive angioplasty.

The session highlighted:

• Modern PCI Strategies: Trading in permanent metallic cages for naturally-restored pulsating vessels.
• Complex Case Presentations: Real-world applications of the bioadaptor in treating calcified complex lesions, bifurcations, and multivessel disease.

These presentations continue to support that the DynamX bioadaptor represents a paradigm shift, promoting adaptive remodeling and restoring natural pulsatility for improved long-term patient outcomes.

#EuroPCR #DynamX #Bioadaptor #PCI #ClinicalData #Cardiology

The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States.

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

PMN 2476 Rev A

[Elixir Medical Corp @ElixirMed]

🩺 Elixir Medical #EuroPCR2026 – Wednesday, May 20 Agenda

Click here to download the full agenda: https://t.co/czUBlbAbfK

Session featuring: @valeriaparadies, @MohanedEgred, Rosli Bin Mohd Ali, @charlottetroui2 , @enrico_cerrato , Vincent On-Hing Kwok

The LithiX HC-IVL system and the DynamX® Coronary Bioadaptor System are CE mark approved and are not available for sale in the United States.

PMN 2477 Rev A

[Elixir Medical Corp @ElixirMed]

See you at #EuroPCR2026.

We’re ready to connect with physicians, share new clinical data, and engage in the conversations that drive the next era of coronary intervention.

#EuroPCR #ElixirMedical #Cardiology #PCI #Innovation

PMN 2473 Rev A

[Elixir Medical Corp @ElixirMed]

Breaking Down Calcium with Precision

LithiX HC-IVL is designed to address the full spectrum of complex calcium morphologies, including nodular, eccentric, and concentric calcium — even in long and tortuous lesions.

LithiX’s ability to create controlled fractures in calcium with a single device helps simplify lesion preparation and facilitate optimal stent expansion in PCI.

Watch the LithiX mechanism of action: https://t.co/2cUr8kKEeL

#LithiX #CalciumModification #IVL #PCI

The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

PMN 2429 Rev A

[Elixir Medical Corp @ElixirMed]

When and Why to Consider a Bioadaptor in PCI Planning

Choosing the right PCI device can make a significant difference in long-term vessel health.

When planning PCI, the DynamX bioadaptor provides an option that supports a return to natural vessel function. Studies have shown it may help reduce the risk of long-term adverse events associated with DES implants.

Consider DynamX bioadaptor for:
·LAD lesions
·Younger patients
·Active patients
·Primary PCI

Visit our Clinical Evidence page to learn more: https://t.co/xKeR6eANwi

#PCI #bioadaptor #DynamX #VesselRestoration

The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States.

Caution: The DynamX Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

PMN 2430 Rev A

[Elixir Medical Corp @ElixirMed]

We’re heading to Paris for #EuroPCR2026, May 19-22.

The global interventional cardiology community will come together in just two weeks! Join us in sharing new data, exchanging ideas, and advancing the future of PCI.

We’re excited to hear from leading physicians presenting new clinical study results and real-world insights on bioadaptor technology, intravascular lithotripsy advances, and site-specific therapy.

Stay tuned for more on our sessions and symposia.

#EuroPCR #ElixirMedical #Cardiology #PCI #Medtech #Innovation

PMN 2470 Rev A

[Elixir Medical Corp @ElixirMed]

Join us at @TurinCTO_CHIP Live 2026

📅 May 6–8, 2026
📍 Turin, Italy

Elixir Medical will be featured across multiple hands-on and live case sessions, including:

🔹 HANDS-ON: CTO Calcium & Imaging Corner (Session 1 & 2)
📅 May 6 | Hall 150 |15:15-16:30 & 18:15-19:30
Two interactive sessions within the NEXT GEN program, providing practical experience in imaging and calcium modification techniques in CTO procedures

🔹 Bioadaptor& LithiX Case (Live Case 3)
📅 May 7 | Auditorium | 11:35-13:30
Real-time insights into PCI strategy and vessel restoration using #DynamX #Bioadaptor and LithiX™ Hertz Contact IVL technologies in complex anatomy
Operators: @AriotiManfredi & @RobertoGarbo1

🔹 LithiX Case
A case demonstration highlighting the role of LithiX™ Hertz Contact IVL in producing a multitude of visible cracks and maximizing stent expansion during complex PCI in lesions with eccentric, concentric or nodular calcium¹

We look forward to contributing to the exchange of techniques and real-world experience in CTO and CHIP interventions.

#TurinCTOCHIP #PCI #CTO #CHIP #Bioadaptor #DynamX #LithiX #HCIVL #Cardiology #ElixirMedical

1. S. Verheye et. al. PINNACLE l EuroIntervention2026;22:255-264

The LithiX HC-IVL system and the DynamX® Coronary Bioadaptor System are CE mark approved and are not available for sale in the United States.

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

PMN 2468 Rev A

[Elixir Medical Corp @ElixirMed]

Are you looking for the next evolution of vascular intervention? Take a deep dive into the DynamX® Coronary Bioadaptor System.

Visit our new LinkedIn showcase page for an in-depth look at the device’s functionality and proven clinical results.

We’ll be updating the page often with product announcements, clinical study results, case studies, and testimonials from physicians who have utilized DynamX in their PCI cases.

https://t.co/YhP8TPd8oP

#ElixirMedical #DynamX #Bioadaptor #VascularIntervention #CoronaryArteryDisease

PMN 2437 Rev A

The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States.

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

[Elixir Medical Corp @ElixirMed]

Elixir Medical has launched a new LinkedIn showcase page for the LithiX™ Hertz Contact Intravascular Lithotripsy (HC-IVL) Catheter.

This page offers more details and regular updates on the novel intravascular lithotripsy device, providing accessible and at-a-glance information for physicians looking for new innovations in coronary calcium treatment.

Visit the LithiX page for clinical evidence results, case studies, expert insights, and more:
https://t.co/fA7vAg6MiE

#ElixirMedical #LithiX #IntravascularDevice #CoronaryCalciumTreatment

PMN 2436 Rev A

Caution: The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

[Elixir Medical Corp @ElixirMed]

What Physicians Are Saying About LithiX

As physicians gain hands-on experience with LithiX™ Hertz Contact IVL, they’re seeing how LithiX supports efficient workflows and successful PCI results in real-world practice.

Watch a video as a panel presents some early LithiX cases: https://t.co/2UfWKAfQdr

#LithiX #PhysicianVoices #PCI #CalciumModification

The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

PMN 2433 Rev A

[Elixir Medical Corp @ElixirMed]

Join us at Danube CHIP & CTO 2026

📅 April 23–24, 2026
📍Vienna, Austria

Elixir Medical will be presenting during the scientific program:
🕑 14:00–14:22
“Streamlining Severe Calcium Modification with LithiX IVL”
Speaker: @JohanBennett2

This presentation will explore approaches to simplifying severe calcium modification in complex PCI using #LithiX #HCIVL. We look forward to contributing to the discussion on advancing treatment strategies in challenging anatomy.

#DanubeCTO #PCI #LithiX #IVL #CalciumModification #Cardiology #ElixirMedical

The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

PMN 2457

[Elixir Medical Corp @ElixirMed]

Complex lesions. Confirmed adaptive remodeling.

The investigator-initiated DYNAMITE Study, now published in The American Journal of Cardiology, evaluated DynamX exclusively in challenging anatomy — long lesions, CTOs, bifurcations, and multi-device cases.

At 9 months, positive vessel remodeling was confirmed by two independent intravascular imaging modalities.

See the data: https://t.co/y9s4SMv3HI

#DynamX #Bioadaptor #PCI #InterventionalCardiology #ClinicalEvidence #IRCCSHumanitasResearchHospital

The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States.

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

PMN 2455 Rev A

[Elixir Medical Corp @ElixirMed]

Join us at the DGK Annual Meeting 2026.

📅 April 9, 2026
📍 Congress Center Rosengarten
Rosengartenplatz 2 - 68161Mannheim

Elixir Medical will participate in two focused sessions addressing challenges in contemporary PCI, featuring #LithiX #IVL and bioadaptive angioplasty with #DynamX Coronary Bioadaptor System.

🔹 Session 1
NEW APPROACHES TO OPTIMIZING PCI RESULTS
13:00 – 14:30
Room 15

Faculty: @GaedeLuise & @tommasoggori , Maren Weferling, @HolgerNef, @NikosWerner, Christoph Liebetrau

🔹 Session 2
Bioadaptor live-in-the-box case: Bifurcation – PCI
08:00 – 09:30
Room 22

Operator: Alexander Ghanem

Join to learn how our versatile #LithiX #IVL optimizes stent expansion regardless of calcium morphology¹ and how #Bioadaptor significantly reduces TLF rate compared to #PCI Standard of care².
These sessions will bring together innovative technologies, clinical evidence, and real-world insights to support decision-making in complex coronary interventions.

#DGK2026 #PCI #Cardiology #ElixirMedical #LithiX #IVL #DynamX #Bioadaptor

1. S. Verheye et. al. PINNACLE l EuroIntervention 2026;22:255-264
2. D. Elinge et. aL. INFINITY-Swedeheart 12 months. The Lancet 2024

The LithiX™ HC-IVL system and the DynamX® Coronary Bioadaptor System are CE mark approved and are not available for sale in the United States.

The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States.

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

PMN 2420 Rev A

[Elixir Medical Corp @ElixirMed]

Join us at the @German_CTOCHIP meeting for a live case with operators Mohamed Ayoub & Masahisa Yamane.

📅 March 28, 2026
🕘 08.30 am
📍 NORD EVENT Panoramadeck
Emporio, Dammtorwall 15, 20355 Hamburg, Germany

Live Case #8:
Protected PCI in CHIP post-CABG

During this live case, operators will demonstrate advanced PCI techniques in a high-risk, post-CABG patient, including the use of #LithiX Hertz Contact Intravascular Lithotripsy for calcium modification.

#LithiX #IVL can be used in lesions with eccentric, concentric, and nodular calcium, producing a multitude of visible cracks.¹

#GermanCTOCHIP #PCI #CHIP #ComplexPCI #InterventionalCardiology #ElixirMedical #IVL

The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

1. S. Verheye et. al. PINNACLE l EuroIntervention2026;22:255-264

PMN 2418 Rev A

[Elixir Medical Corp @ElixirMed]

Join us at the Milano Calcium Course for a live case performed by Giuseppe Sangiorgi & @daniab86

📅 March 26, 2026
📍 Milan, Italy

🕒 15:00 – 16:00
Live 3 | Policlinico Tor Vergata – Rome

This live case session will explore strategies for treating complex coronary calcification with versatile PCI techniques, including #LithiX #IVL.

#LithiX Hertz Contact Intravascular Lithotripsy (HC-IVL) creates deep, wide cracks in lesions with eccentric, concentric, or nodular calcium without damaging soft tissue.¹

#MilanoCalciumCourse #PCI #Cardiology #CoronaryCalcification #ElixirMedical #LithiX #IVL

The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

1. S. Verheye et. al. PINNACLE l EuroIntervention2026;22:255-264

PMN 2416 Rev A

[Elixir Medical Corp @ElixirMed]

Join us at #CathlabOfTheFuture 2026

Maximizing Outcomes in Heavily Calcified LAD: Breaking Through with Novel Techniques

📍 Portoroz, Slovenia | March 6–7
🗓️ March 6 | 13:30–14:30

Scientific Symposium sponsored by Elixir Medical

Moderator: @MohanedEgred
Faculty: Irzal Hadzibegovic, @DamianoRegazzo1, Maximilian Will

This session will explore innovative strategies for PCI.
Speakers will be discussing the importance of vessel function restoration to improve PCI outcomes as well as how to optimize stent expansion regardless of calcium morphology with #LithiX #IVL.

#PCI #Bioadaptor #LithiX #IVL #Cardiology

The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States.

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

PMN 2410 Rev A

[Elixir Medical Corp @ElixirMed]

Join us at #Euro4C 2026 for a symposium on the role of LithiX Hertz Contact IVL in calcium fragmentation. The session will highlight the mechanism of action for LithiX Hertz Contact IVL, the clinical evidence and real-world case discussions of calcium modification in PCI.

Faculty: @HontonB , @JEscaned , @enrico_cerrato , @HawranekMichal , @valeriaparadies

📅 Friday, 27 February 2026
🕓 16:00–17:00 | Main Room, Session ID 41390

#Euro4C2026 #LithiX #IVL #PCI #CalciumModification

The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States.

PMN 2397 Rev A

[Elixir Medical Corp @ElixirMed]

Join us at DEBS 2026 in Rome, Italy

📅 February 19–20, 2026

Elixir Medical is pleased to participate in this year’s DEBS program with presentations focused on calcium modification and Bioadaptor vs. DCB strategies.

🔹 Live Case: Calcium Modification with LithiX
Operator: @BenedittoDi

🔹 Session 15: Innovation Corner: Bioadaptor vs DCB
Featuring: G.M. Sangiorgi

We look forward to contributing to the discussion on next-generation coronary therapies.

PMN 2392 Rev A

#DEBS2026 #LithiX #Bioadaptor #IVL #PCI #Cardiology #ElixirMedical

[Elixir Medical Corp @ElixirMed]

ICYMI: At TCT 2025, Dr. David Erlinge presented new real-world comparative data on PCI outcomes using bioadaptors vs drug-coated balloons (DCB) for de novo coronary lesions.

Using propensity score-matched data from the SCAAR registry, this 2-year analysis included a clinically complex population with >70% ACS patients in both treatment arms.

“In this study, the bioadaptor was associated with a better 2-year outcome compared to DCB.” – Dr. David Erlinge

Primary composite outcome (target segment revascularization, TV-MI, or all-cause mortality):
– Bioadaptor: 4.9%
– DCB: 9.7%

View the full presentation: https://t.co/KxdhB1V5zO

The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States.

Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use.

PMN 2315 Rev A